Medicina, Volume 62, Issue 1
2026 January - 234 articles
Cover Story: Oral Janus kinase (JAK) inhibitors are rapidly expanding beyond their approved indications in dermatology. This review synthesizes real-world evidence from case reports and series describing off-label use of baricitinib, abrocitinib, upadacitinib, and ritlecitinib across a wide spectrum of inflammatory skin diseases. Autoimmune bullous, neutrophilic, lichenoid, granulomatous, follicular, and pruritic dermatoses frequently showed rapid and sustained clinical responses, often after failure of conventional therapies. The broad immunomodulatory activity of JAK inhibition enables disease control across heterogeneous pathogenic pathways, with generally favorable tolerability. These findings highlight the emerging role of oral JAK inhibitors as versatile therapeutic options in selected, refractory dermatologic conditions. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
